Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience

Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience

Breast and prostate cancer have a propensity to metastasize to bones and cause osteolysis and abnormal new bone formation. Metastases locally disrupt normal bone remodeling. Although metastases from prostate cancer have been classified as osteoblastic based on the radiographic appearance of the lesi...

Full description

Bibliographic Details
Main Authors: Nigora Rasulova, Vladimir Lyubshin, Dauranbek Arybzhanov, Valery Krylov, Marat Khodjibekov
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:World Journal of Nuclear Medicine
Subjects:
Bone metastases
Sm-153 systemic radionuclide therapy
Xgeva (Denosumab)
Online Access:http://www.wjnm.org/article.asp?issn=1450-1147;year=2013;volume=12;issue=1;spage=19;epage=23;aulast=Rasulova

Internet

http://www.wjnm.org/article.asp?issn=1450-1147;year=2013;volume=12;issue=1;spage=19;epage=23;aulast=Rasulova

Similar Items